Table A. SARS-CoV-2 Variants Currently or Recently Circulating in the United States and Their Susceptibility to Anti-SARS-CoV-2 Monoclonal Antibodies
Last Updated: December 28, 2022
For information on SARS-CoV-2 variants that were previously circulating in the United States, see the Guidelines Archive.
WHO Label and Pango Lineage | BEB | TIX Plus CILa | BAM Plus ETE | CAS Plus IMD | SOT | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
In Vitro Susceptibilityb | Anticipated Clinical Activity | In Vitro Susceptibilityb | Anticipated Clinical Activity | In Vitro Susceptibilityb | Anticipated Clinical Activity | In Vitro Susceptibilityb | Anticipated Clinical Activity | In Vitro Susceptibilityb | Anticipated Clinical Activity | |||
Omicron BA.5 | No change | Active | Moderate reduction | Active | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active | ||
Omicron BA.4.6/BF.7 | No change | Active | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active | ||
Omicron BQ.1 | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active | ||
Omicron BQ.1.1 | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active | ||
Omicron XBB | Marked reduction1,2 | Unlikely to be active | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active | ||
a Other variants are expected to be resistant to TIX plus CIL (e.g., BA.5.2.6, BF.11, BA.2.75.2). However, these variants currently represent a small proportion of the circulating variants in the United States.
Key: BAM = bamlanivimab; BEB = bebtelovimab; CAS = casirivimab; CIL = cilgavimab; ETE = etesevimab; EUA = Emergency Use Authorization; FDA = Food and Drug Administration; IMD = imdevimab; SOT = sotrovimab; TIX = tixagevimab; WHO = World Health Organization |
References
- Imai M, Ito M, Kiso M, et al. Efficacy of antiviral agents against Omicron subvariants BQ.1.1 and XBB. N Engl J Med. 2022. Available at: https://www.ncbi.nlm.nih.gov/pubmed/36476720.
- Wang Q, Iketani S, Li Z, et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2022;Published online ahead of print. Available at: https://www.ncbi.nlm.nih.gov/pubmed/36580913.
- Food and Drug Administration. Fact sheet for health care providers: Emergency Use Authorization (EUA) of bamlanivimab and etesevimab. 2022. Available at: https://www.fda.gov/media/145802/download.
- Food and Drug Administration. Fact sheet for health care providers: Emergency Use Authorization (EUA) of REGEN-COV (casirivimab and imdevimab). 2021. Available at: https://www.fda.gov/media/145611/download.
- Food and Drug Administration. Fact sheet for healthcare providers: Emergency Use Authorization (EUA) of sotrovimab. 2022. Available at: https://www.fda.gov/media/149534/download.
- Food and Drug Administration. Fact sheet for healthcare providers: Emergency Use Authorization for Evusheld (tixagevimab co-packaged with cilgavimab). 2022. Available at: https://www.fda.gov/media/154701/download.
- Food and Drug Administration. Fact sheet for healthcare providers: Emergency Use Authorization for bebtelovimab. 2022. Available at: https://www.fda.gov/media/156152/download.